logo conference-reports

Conference Reports

Educational funding by logo MSD Oncology

SABCS 2018 — Adjuvant T-DM1 may be the new standard for high-risk HER2+ breast cancer

KATHERINE shows 50% lower recurrence vs trastuzumab in patients with residual disease.